The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

Dr Philip Mease shares his clinical insights for diagnosing and treating fibromyalgia and psoriatic arthritis.

In 2019, BMS made a big bet on Sotyktu by deciding to keep the then-pipeline asset despite its pending acquisition of Celgene. Based on that decision, BMS sold its mega-blockbuster Otezla to Amgen for ...

Pooled data from PsA and axSpA extension studies provide early reassurance ...

Key Summary The transition from psoriasis to psoriatic arthritis (PsA) is driven by several modifiable risk factors, ...

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...

Bristol Myers wins FDA approval to expand Sotyktu for psoriatic arthritis after strong POETYK study data, adding a new indication for the TYK2 inhibitor.

Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...

The results from two recent clinical trials reinforce that treating obesity alongside inflammation can improve quality of life for many people with psoriatic diseases. In clinical trials involving ...

A t first glance, psoriasis is a skin disease: Skin symptoms likely led to your diagnosis, and if you’ve dealt with the stigma of psoriasis from others, it was probably because of visible skin lesions ...

Investigators recently examined clinical risk factors in the context of novel molecular biomarkers to predict progression of psoriasis to PsA. Nail involvement was found to be a strong predictor of ...